SMPD1 and neoplasm: Our observation show that scheduling of antiangiogenic drug delivery precisely at 1 hour prior to anticancer therapy to derepress ASMase/ceramide signaling of endothelial cell injury and enhance tumor response differs from this conventional use of antiangiogenic drugs and has yet to be tested clinically.